Ruth Ruddle

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Topics

Metastatic Breast Cancer

Cell Proliferation

Dna Damage Response

Top Venues

Cancer discovery

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Christina Guo, Adam Sharp, Bora Gurel, Mateus Crespo, Ines Figueiredo, Suneil Jain, Ursula Vogl, Jan Rekowski, Mahtab Rouhifard, Lewis Gallagher, Wei Yuan, Suzanne Carreira, Khobe Chandran, Alec Paschalis, Ilaria Colombo, Anastasios Stathis, Claudia Bertan, George Seed, Jane Goodall, Florence I Raynaud, Ruth Ruddle, Karen E Swales, Jason Malia, Denisa Bogdan, Crescens Tiu, Reece Caldwell, Caterina Aversa, Ana Ferreira, Antje Neeb, Nina Tunariu, Daniel Westaby, Juliet Carmichael, Maria de Los Dolores Fenor de la Maza, Christina Yap, Ruth Matthews, Hannah Badham, Toby Prout, Alison Turner, Mona Parmar, Holly Tovey, Ruth Riisnaes, Penny Flohr, Jesús Gil, David Waugh, Shaun Decordova, Anna Schlag, Bianca Calì, Andrea Alimonti, Johann S de Bono
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature (2023)
Elizabeth A Coker, Adam Stewart, Bugra Ozer, Anna R Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary Er O'Brien, Florence Raynaud, Johann S de Bono, Bissan Al-Lazikani, Udai Banerji
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes. Molecular cancer therapeutics 21 (6) (2022)
Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, Alvaro H Ingles Garces, Andrea Biondo, Ionut-Gabriel Funingana, Martin Little, Ruth Ruddle, Florence I Raynaud, Ruth Riisnaes, Bora Gurel, Sue Chua, Nina Tunariu, Joanna C Porter, Toby Prout, Mona Parmar, Anna Zachariou, Alison Turner, Ben Jenkins, Stuart McIntosh, Ed Ainscow, Anna R Minchom, Juanita Lopez, Johann S de Bono, Robert Jones, Emma C Hall, Natalie Cook, Bristi Basu, Udai Banerji
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (21) (2022)
Diana M Carvalho, Peter J Richardson, Nagore Olaciregui, Reda Stankunaite, Cinzia Lavarino, Valeria Molinari, Elizabeth A Corley, Daniel P Smith, Ruth Ruddle, Adam Donovan, Akos Pal, Florence I Raynaud, Sara Temelso, Alan Mackay, John P Overington, Anne Phelan, David Sheppard, Andrew Mackinnon, Bassel Zebian, Safa Al-Sarraj, Ashirwad Merve, Jeremy Pryce, Jacques Grill, Michael Hubank, Ofelia Cruz Martinez, Andres Morales La Madrid, Sabine Mueller, Angel Montero Carcaboso, Fernando Carceller, Chris Jones
Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. Cancer discovery (2021)
Robert McLeod, Rajiv Kumar, Dionysis Papadatos-Pastos, Joaquin Mateo, Jessica S Brown, Alvaro H Ingles Garces, Ruth Ruddle, Shaun Decordova, Simone Jueliger, Roberta Ferraldeschi, Oscar Maiques, Victoria Sanz-Moreno, Paul Jones, Stephanie Traub, Gavin W Halbert, Sarah Mellor, Karen E Swales, Florence I Raynaud, Michelle D Garrett, Udai Banerji
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (18) (2020)
Javier Pascual, Joline S J Lim, Iain R J Macpherson, Anne C Armstrong, Alistair Ring, Alicia F C Okines, Rosalind J Cutts, Maria Teresa Herrera-Abreu, Isaac Garcia-Murillas, Alex Pearson, Sarah Hrebien, Heidrun Gevensleben, Paula Z Proszek, Michael Hubank, Margaret Hills, Jenny King, Mona Parmar, Toby Prout, Laura Finneran, Jason Malia, Karen E Swales, Ruth Ruddle, Florence I Raynaud, Alison Turner, Emma C Hall, Timothy Anthony Yap, Juanita S Lopez, Nicholas C Turner
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer discovery 11 (1) (2020)
Timothy Anthony Yap, Rebecca S Kristeleit, Vasiliki Michalarea, Stephen J Pettitt, Joline S J Lim, Suzanne Carreira, Desamparados Roda, Rowan Miller, Ruth Riisnaes, Susana Miranda, Ines Figueiredo, Daniel Nava Rodrigues, Sarah Ward, Ruth Matthews, Mona Parmar, Alison Turner, Nina Tunariu, Neha Chopra, Heidrun Gevensleben, Nicholas C Turner, Ruth Ruddle, Florence I Raynaud, Shaun Decordova, Karen E Swales, Laura Finneran, Emma C Hall, Paul Rugman, Justin P O Lindemann, Andrew Foxley, Christopher J Lord, Udai Banerji, Ruth Plummer, Bristi Basu, Juanita S Lopez, Yvette Drew, Johann S de Bono
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers. Cancer discovery 10 (10) (2020)